BioCryst Pharmaceuticals, Inc. (BCRX) has entered into a definitive agreement to sell its European ORLADEYO® (berotralstat) business to Neopharmed Gentili for up to $264 million.
The company plans to use the proceeds to retire all remaining term debt from Pharmakon, eliminating approximately $70 million in future interest payments.
BioCryst Pharmaceuticals now expects to end 2027 with about $700 million in cash and no term debt, marking an increase of $400 million compared to prior 2027 net cash guidance.
Upon closing, expected by early October, Neopharmed Gentili will pay $250 million upfront for the European assets and rights related to ORLADEYO, with up to $14 million in future milestones tied to sales in Central and Eastern Europe.
